Michael E. Engel

Michael E. Engel, MD, PhD, FAAP

Languages spoken: English

Academic Information

Departments Adjunct - Pediatrics

Divisions: Hematology/Oncology

Board Certification

  • American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
  • American Board of Pediatrics (Pediatrics)

Michael Engel, MD, PhD, attended the Vanderbilt University School of Medicine in Nashville, TN. He completed his Pediatric residency training and subspecialty training in Pediatric Hematology/Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt.


Dr. Engel's clinical interests encompass hematologic and oncologic illness in children, adolescents and young adults, with an emphasis on hematologic malignancies including myeloid and lymphoid leukemias.

Dr. Engel is a past recipient of a National Young Investigator award from the American Society of Pediatric Hematology/Oncology, a Ruth Kirschstein fellowship from the National Cancer Institute, a young investigator award from Alex's Lemonade Stand Pediatric Cancer Research Foundation, and served as a Hyundai Hope on Wheels Foundation Scholar. His research is currently supported by a Research Scholar Award from the St. Baldrick's Pediatric Cancer Research Foundation, research grants from CureSearch and Hope Street Kids foundations and a K08 Career Development Award from the National Institutes of Health. In the clinical setting, Dr. Engel is the recipient of a prestigious PRC Top Performer Award for 100th percentile patient satisfaction.

Education History

Undergraduate Purdue University, West Lafayette Campus
 BS
Other Training Vanderbilt University School of Medicine
Doctoral Training Vanderbilt University School of Medicine
 PhD
Professional Medical Vanderbilt University School of Medicine
 MD
Residency Vanderbilt University Medical Center
 Resident
Fellowship Vanderbilt University Medical Center
 Clinical Fellow
Research Fellow Vanderbilt University Medical Center
 Research Fellow

Selected Publications

Journal Article

  1. Mixon BA, Eckrich MJ, Lowas S, Engel M (2013). Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma. Journal of pediatric hematology/oncology, 35(4), e163-6.
  2. Fagan E, Slone J, Shoemaker A, Black J, Berlin J, Engel M (2012). Neuroendocrine carcinoma in an adolescent with hypercortisolemia. Journal of pediatric hematology/oncology, 34(3), 117-119.
  3. Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams C (2012). Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. PloS one, 7(12), e51205.
  4. Engel ME, Nguyen HN, Mariotti J, Hunt A, Hiebert S (2010). Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. Molecular and cellular biology, 30(7), 1852-63.
  5. Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, Engel M, Hiebert S (2008). Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Molecular and cellular biology, 28(20), 6234-47.
  6. Frangoul H, Wills M, Crossno C, Engel M, Domm (2007). Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatric transplantation, 11(8), 942-4.
  7. Engel ME, Hickstein DD, Bauer TR Jr, Calder C, Manes B, Frangoul (2006). Matched unrelated bone marrow transplantation with reduced-intensity conditioning for leukocyte adhesion deficiency. Bone marrow transplantation, 37(7), 717-8.
  8. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses H (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Molecular biology of the cell, 12(1), 27-36.
  9. Engel ME, McDonnell MA, Law BK, Moses H (1999). Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. The Journal of biological chemistry, 274(52), 37413-20.
  10. Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh M (1998). Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology, 139(8), 3620-8.
  11. Engel ME, Datta PK, Moses H (1998). RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation. The Journal of biological chemistry, 273(16), 9921-6.
  12. Kawabata M, Imamura T, Miyazono K, Engel ME, Moses H (1995). Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha. The Journal of biological chemistry, 270(50), 29628-31.
  13. Vedvick T, Buckholz RG, Engel M, Urcan M, Kinney J, Provow S, Siegel RS, Thill G (1991). High-level secretion of biologically active aprotinin from the yeast Pichia pastoris. Journal of industrial microbiology, 7(3), 197-201.

Review

  1. Engel ME, Datta PK, Moses H (1998). Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. Journal of cellular biochemistry. Supplement, 30-31, 111-22.

Book Chapter

  1. Engel ME, and Hiebert S (2010). Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. 145, 127-147.

Abstract

  1. Andrade D, Singe J, Bareyan D, McClellan D, Lucente H, Chandrasekharan M, and Engel M (2013). Notch and PIAS3 differentially regulate sumoylation of GFI1 to modulate transcriptional repression.
  2. Andrade D, Maese L, Singer J, Bareyan D, McClellan D, Lucente H, Quinton R, Chandrasekharan M, Liu F, and Engel M (2013). Sumoylation regulates the half-life of Growth Factor Independence (GFI)-1 to modulate transcriptional repression.
  3. Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S and Engel M (2013). Lysine Specific Demethylase-1 inhibition as a therapeutic strategy that leverages the requirement for Growth Factor Indepndence-1 in Notch-driven T-ALL.
  4. Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S, Maese L and Engel M (2013). Notch alters sumoylation to govern GFI1 protein stability and support its transcriptional repression function.
  5. Andrade DL, Bareyan D, Singer J, Quinton R, Engel M (2012). Regulation of GFI1 proteins by Notch intracellular domains.
  6. Mangrum DS, Shams S, Downie J, von Schwelder U, Rodic V, Engel ME, Barnette P, Frazer JK, Trede N, Pei D, Cheng C, Mullighan C, Yang J, Miles R, Schiffman J (2011). Focal 22q11.22 loss combined with IKZF1 alterations predict very poor outcome in childhood acute lymphoblastic leukemia.
  7. Mariotti J, Nguyen HN and Engel M (2010). Structure'function relationships between RUNX1-MTG fusion proteins and core components of the Notch transcription complex.

Other

  1. Engel ME, Hiebert S (2010). The enemy within: dormant retroviruses awaken. Nature medicine, 16(5), 517-8.
  2. Engel M (1999). Rho GTP-Binding Proteins and the C-Jun N-Terminal Kinase Cascade. Ph.D. Thesis.